IMRX - immuneering.com Price to Earnings Adjusted for Growth Rate

Immuneering Corporation (IMRX) brings together experts in bioinformatics and medicine, attracting talent through stock options and the prospect of breakthrough discoveries. The history of the PEG ratio demonstrates valuation dynamics, where the 0.00 indicator expresses the state of the metric. Immuneering Corporation (IMRX) implements IT algorithms to create targeted drugs, however, high development costs and the uncertainty of clinical trials create significant financial risks.

IMRX: immuneering.com Price/Earnings to Growth Multiple 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for Immuneering Corporation (IMRX)

- market value and analyst target forecast:

Price Rate Chart Immuneering Corp|IMRX - Consensus Target

- market capitalization statistics:

Market Value Immuneering Inc.|IMRX - Real Price to Acquire Entire Company

- shareholders' equity book value data:

Accounting Value of a Share Immuneering|IMRX - Company Net Assets|Market Cap to Book Value Multiple immuneering.com|IMRX - Company Total Assets

- business debt structure and liquidity details:

- earnings and valuation multiples information:

IMRX - Net Profit|Expected Net Profit Immuneering Corporation|IMRX - P/E Multiple|Price to Future Earnings Ratio Immuneering Corp.|IMRX - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Immuneering Inc.|IMRX - Operating profit before deduction of amortization|Earnings per share for the last four quarters Immuneering|IMRX - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months immuneering.com|IMRX - Earnings growth in current year|Expected net earnings per share growth next year Immuneering Corporation

- sales revenue and business income indicators:

IMRX - Company Revenue|Company Future Revenue Immuneering Corp|IMRX - P/S Multiple|Forward P/S Multiple Immuneering Inc.

General company analysis:Immuneering Corporation

The development of MAPK inhibitors to combat solid tumors makes Immuneering Corporation (IMRX) dependent on the future success of clinical trials for the drug IMM-1-104. By analyzing the P/E growth trend, an investor assesses the cost of each percentage of expected profit growth, which allows for the identification of an undervalued asset when values fall below one, provided that the pace of business expansion outstrips the current market multiplier.

Competing companies

Genmab AS (GMAB) - Price to Net Income Growth Ratio|Exelixis Corp - Price/Earnings to Growth Multiple|Nuvalent Therapeutics (NUVL) - Price to Earnings Adjusted for Growth Rate|KYMR: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio IDYA (ideayabio.com)|ELVN (Enliven Therapeutics, Inc.) - Price/Earnings to Growth Multiple|ORIC: Company Value to Earnings Growth Ratio|RLAY (Relay Pharma) - PEG Multiple|PEG Multiple Nurix Corp|Price/Earnings to Growth Ratio Tyra Biosciences, Inc. (TYRA)|VSTM (verastem.com) - Growth-Adjusted Payback Ratio|PEG Multiple GLUE (Monte Rosa Therapeutics, Inc.)|Price to Net Income Growth Ratio Cullinan Oncology|C4 Tx - PEG Multiple|Price to Earnings Adjusted for Growth Rate Black Diamond Therapeutics, Inc|RPTX (Repare Therapeutics) - Price/Earnings to Growth Multiple|PMVP: Company Value to Earnings Growth Ratio|KPTI (Karyopharm Therapeutics, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Propanc Biopharma, Inc. PPCB|PEG Multiple BGMS|aadibio.com - Growth-Adjusted P/E Ratio|Aileron Therapeutics, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio BPMC|GLYC: Price/Earnings to Growth Multiple|SpringWorks Therapeutics Inc. - Company Value to Earnings Growth Ratio